• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Consumer Cyclical·BYND
Share

Beyond Meat, Inc. Stocks

$ 10.03Last Updated 23.09.2026

Issuer Rating

3/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 199.27M

$ 10.03
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

07.05.2026 18:29

Beyond Meat sinking on weak forecast second-quarter sales amid sluggish demand

17.03.2026 17:01

Beyond Meat shares selling off on annual report delay, preliminary 4Q revenue

17.03.2026 15:35

Morning in New York: negative background intensifies

11.11.2025 16:42

From rally to rout: Beyond Meat keeps sliding after disappointing 3Q earnings

30.10.2025 18:51

Shorts are coming after small- and mid-cap stocks. Which names are feeling pressure?

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Beyond Meat, Inc. engages in the provision of plant-based meats. Its products include ready-to-cook meat under The Beyond Burger and Beyond Sausage brands, and frozen meat, namely, Beyond Chicken Strips and Beyond Beef Crumbles. The company was founded by Ethan Walden Brown and Brent Taylor in 2009 and is headquartered in El Segundo, CA.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of BYND is 12.3 and suggests 23% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.09.2026 16:11

Shares of CareDx, a medical test developer, soared to a 5-year high. Why?

25.09.2026 15:45

"Hacker Club" Incidents: How Errors in AI Tests Created New Risks for Investors

25.09.2026 15:30

BlackRock sees Kazakhstan and Uzbekistan as new investment hubs

25.09.2026 15:20

Morning in New York: Inflation Expectations in the Spotlight

25.09.2026 15:00

ADARx IPO: A developer of treatments for rare diseases and an AbbVie partner has gone public

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026